{"id":"alogliptin-and-glimepiride","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypoglycemia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alogliptin works by blocking the action of DPP-4, an enzyme that breaks down incretin hormones, thereby increasing the levels of incretin hormones. Glimepiride, on the other hand, stimulates insulin release from the pancreatic beta cells, thereby lowering blood glucose levels.","oneSentence":"Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and glimepiride is a sulfonylurea that stimulates insulin release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:13.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT04470310","phase":"PHASE4","title":"Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-12-31","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT02528019","phase":"PHASE4","title":"Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-08","conditions":"Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications","enrollment":100},{"nctId":"NCT02426294","phase":"PHASE4","title":"Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT01318135","phase":"PHASE2, PHASE3","title":"Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Type 2 Diabetes Mellitus","enrollment":576},{"nctId":"NCT01318083","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Type 2 Diabetes Mellitus","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SYR-322","Amaryl"],"phase":"phase_2","status":"active","brandName":"Alogliptin and glimepiride","genericName":"Alogliptin and glimepiride","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and glimepiride is a sulfonylurea that stimulates insulin release. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}